As COVID-19 and its variants continue their attack, the agency maintains its position of overseer and giver of advice on various treatments and vaccines.
The cancer-centric pharma firm will collaborate with the Philadelphia-based cancer center to pinpoint new indications and biomarkers for its drug candidate.
A leader from the global clinical research logistics company shares how to weigh the complex aspects of a decentralized trial and craft intelligent strategy.
According to a leader from the health engagement solutions firm, intelligent use of technology tools can add patient-centricity and realism to a study.
Swift Skin and Wound is a digital imaging technology designed to support decentralized clinical trials conducted to evaluate skin and wound treatments.
Two experts from the contract research organization offer advice on planning and executing clinical studies with the unique needs of such patients in mind.
Stakeholders in the Rare Disease Cures Accelerator-Data and Analytics Platform initiative are partnering in hopes of bringing treatments to patients faster.
The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.
This month’s roundup of new technology, equipment, and industry partnerships includes news from IBM, IQVIA, Mediata, Labcorp, and other notable companies.
A physician assistant from Hawthorne Effect shares how she and other trained health professionals contribute their knowledge and talents to in-home studies.
A survey commissioned by Bristol Myers Squibb reveals healthcare providers are confident that immunotherapy can positively impact earlier-stage cancers.
The advocacy organization's PIE4CNS initiative is aimed at targeting and reducing gaps in diagnosis, research, and trials for rare neurological conditions.
The US medical research agency plans to offer funding over five years through a newly launched consortium, expected to include 30 sites across the country.
The two companies are collaborating on development of Myfembree, a combination therapy to treat the painful condition affecting millions of women worldwide.
The US agency continues to oversee vaccine and drug development, and to share information and advice for life-sciences professionals and civilians alike.
